Trending...
- New Home of the Month: Spacious Luxury Meets Modern Design in The Bristol at Heritage at Manalapan
- Joseph Nybyk aka Neibich of Gilbert, Arizona
- Tacoma: Homicide Investigation – 1200 block of South M Street
SEATTLE--(BUSINESS WIRE)--Myosana Therapeutics, Inc., pioneer of a muscle-specific non-viral gene therapy platform for neuromuscular and cardiac diseases, today announced the completion of a seed funding round totaling over $5 million led by investor John Ballantyne, Ph.D. The capital will go toward developing Myosana's platform with the goal of identifying the first development candidate for Duchenne muscular dystrophy by 2025.
"Built on decades of expertise in neuromuscular diseases, Myosana's muscle-specific non-viral gene therapy platform is poised to change the way patients are treated for neuromuscular and cardiac diseases," said Ballantyne, Cofounder and former longtime CSO of Biologics CDMO-Aldevron, and a Founder of therapeutic delivery system developer Agathos. "Myosana's progress building on the platform's promising in vivo data is an essential next step. I'm excited to partner with the company as it pushes ahead toward a therapy that will reach patients and improve their lives."
New investments from the Muscular Dystrophy Association and Parent Project Muscular Dystrophy (PPMD) rounded out the seed round, building on capital from original Myosana investor CureDuchenne Ventures and early investor PPMD a year later.
More on Washingtoner
Completion of this major funding round comes just as Myosana has appointed its new CEO, Dr. Matthew Lumley. A board member since 2021, Lumley is a physician scientist who has spent nearly two decades in academic medicine and drug development, cultivating expertise in translational medicine and early clinical development in complex pediatric diseases. Lumley is also the father of a son with Duchenne muscular dystrophy. In his role on Myosana's Board of Directors, Lumley has been intimately involved in raising seed funding and advancing the platform.
"Dr. Ballantyne's expertise in the nucleic acid production and delivery spaces builds credibility in our approach. His investment, alongside our nonprofit partners, will go directly to platform optimization and the identification of a development candidate for Duchenne muscular dystrophy in the next 18-24 months," said Lumley. "As proof of principle for the platform, success in treating Duchenne would open up opportunities for Myosana to target a large range of neuromuscular and cardiac diseases."
Alongside his role as CEO of Myosana, Lumley is a Venture Partner at Medicxi, a life sciences-focused venture capital firm where he is involved in the formation and financing of biotechnology companies across the full drug development continuum. His recent roles include Senior Director of Rare Disease Clinical Development at Moderna and Medical Director of Rare Diseases at Pfizer.
About Myosana Therapeutics
Myosana Therapeutics, Inc., has pioneered a muscle-specific non-viral gene therapy platform for neuromuscular and cardiac diseases. Based on this platform, the company is developing new gene therapies that will potentially transform progressive neuromuscular and cardiac diseases, increasing longevity and improving quality of life. Myosana's first clinical candidate from the platform will be delivery of full-length dystrophin as a therapy for Duchenne muscular dystrophy.
More on Washingtoner
Myosana's esteemed leadership team includes cofounders Stan Froehner, Ph.D., and Nick Whitehead, Ph.D., both internationally known experts in neuromuscular disease from the University of Washington, whose decades-long careers are marked by significant milestones. Dr. Froehner discovered the syntrophin proteins in muscle's dystrophin complex and developed several pre-clinical treatments for muscular dystrophy. Dr. Whitehead has uncovered mechanisms of muscle weakness in Duchenne muscular dystrophy and developed Myosana's innovative non-viral platform. The platform overcomes the significant limitations of viral vector-delivered gene therapy for muscle disease by providing targeted muscle delivery, large gene capacity, repeat dosing, and immune neutrality.
To learn more and follow Myosana's progress toward its first clinical development candidate, visit us at www.myosanatherapeutics.com.
Contacts
Kara Stephens-Weaver
407-765-1185
kara.stephens-weaver@precisionvh.com
"Built on decades of expertise in neuromuscular diseases, Myosana's muscle-specific non-viral gene therapy platform is poised to change the way patients are treated for neuromuscular and cardiac diseases," said Ballantyne, Cofounder and former longtime CSO of Biologics CDMO-Aldevron, and a Founder of therapeutic delivery system developer Agathos. "Myosana's progress building on the platform's promising in vivo data is an essential next step. I'm excited to partner with the company as it pushes ahead toward a therapy that will reach patients and improve their lives."
New investments from the Muscular Dystrophy Association and Parent Project Muscular Dystrophy (PPMD) rounded out the seed round, building on capital from original Myosana investor CureDuchenne Ventures and early investor PPMD a year later.
More on Washingtoner
- Industrial and systems engineers celebrate key leaders in the field at IISE Annual Conference
- Cosanostra Miami Rises as the Best Latin Nightclub in Miami in Under Two Years From its Opening
- CCHR Leader's 50-Year Fight for Psychiatric Drug Victims Gains National Momentum
- Author Releases 7-Day Screen Time Reset for Families as Teachers Worldwide Report Children "Struggling to Grasp Basic Concepts"
- Men's Health Month Begins with Record Proclamations, AP News Coverage, & National Momentum for Men's Health
Completion of this major funding round comes just as Myosana has appointed its new CEO, Dr. Matthew Lumley. A board member since 2021, Lumley is a physician scientist who has spent nearly two decades in academic medicine and drug development, cultivating expertise in translational medicine and early clinical development in complex pediatric diseases. Lumley is also the father of a son with Duchenne muscular dystrophy. In his role on Myosana's Board of Directors, Lumley has been intimately involved in raising seed funding and advancing the platform.
"Dr. Ballantyne's expertise in the nucleic acid production and delivery spaces builds credibility in our approach. His investment, alongside our nonprofit partners, will go directly to platform optimization and the identification of a development candidate for Duchenne muscular dystrophy in the next 18-24 months," said Lumley. "As proof of principle for the platform, success in treating Duchenne would open up opportunities for Myosana to target a large range of neuromuscular and cardiac diseases."
Alongside his role as CEO of Myosana, Lumley is a Venture Partner at Medicxi, a life sciences-focused venture capital firm where he is involved in the formation and financing of biotechnology companies across the full drug development continuum. His recent roles include Senior Director of Rare Disease Clinical Development at Moderna and Medical Director of Rare Diseases at Pfizer.
About Myosana Therapeutics
Myosana Therapeutics, Inc., has pioneered a muscle-specific non-viral gene therapy platform for neuromuscular and cardiac diseases. Based on this platform, the company is developing new gene therapies that will potentially transform progressive neuromuscular and cardiac diseases, increasing longevity and improving quality of life. Myosana's first clinical candidate from the platform will be delivery of full-length dystrophin as a therapy for Duchenne muscular dystrophy.
More on Washingtoner
- AdvisorVault Adds Social Media Archiving to its Consolidated D3P Service
- UK Financial Ltd Audits Full Ethereum Architecture Verifies Corporate Wallets and 19-Token Ecosystem Ahead of CoinMarketCap Filing for Global Ranking
- Spokane: Flags Lowered for the Victims of the Longview Tragedy
- Creative Investment Research Analysis Finds Slower GDP Growth, Rising Inflation
- Award-winning author Diana Colleen Explores Psychedelic Therapy, Climate Change and Billionaire-ism
Myosana's esteemed leadership team includes cofounders Stan Froehner, Ph.D., and Nick Whitehead, Ph.D., both internationally known experts in neuromuscular disease from the University of Washington, whose decades-long careers are marked by significant milestones. Dr. Froehner discovered the syntrophin proteins in muscle's dystrophin complex and developed several pre-clinical treatments for muscular dystrophy. Dr. Whitehead has uncovered mechanisms of muscle weakness in Duchenne muscular dystrophy and developed Myosana's innovative non-viral platform. The platform overcomes the significant limitations of viral vector-delivered gene therapy for muscle disease by providing targeted muscle delivery, large gene capacity, repeat dosing, and immune neutrality.
To learn more and follow Myosana's progress toward its first clinical development candidate, visit us at www.myosanatherapeutics.com.
Contacts
Kara Stephens-Weaver
407-765-1185
kara.stephens-weaver@precisionvh.com
1 Comment
- unity asset store.:
Build real-time 3D projects for various industries across games, animation, automotive, architecture, and more with Unity Asset Store. Start creating with Unity today!
Latest on Washingtoner
- Spokane: SPD Releases Name of Officer Involved in OIS on North Cincinnati
- Spokane: Civics 101: How To Engage With Council Workshop
- Bestselling author Diana Colleen Explores the Psychology of Billionaires in New Podcast Interview
- Kryptokasinot.io Raises Concerns Over Proposed Cryptocurrency Restrictions in Finland's Gambling Reform
- New Home of the Month: Spacious Luxury Meets Modern Design in The Bristol at Heritage at Manalapan
- The Calida Group Announces Sale of Ely at Fort Apache for $57.5 Million
- Summer Festivals in Gunma Prefecture: Song, Dance, and Vibrant Color – Get There Via Tobu Railway!
- Jetperch Introduces Joulescope JS320 Precision Energy Analyzer for Low-Power Embedded System Development
- AI-Powered Trading Bots Are Transforming Forex, Gold, and Digital Markets as DefiHash Expands Intelligent Quantitative Infrastructure
- Early Bird Registration Open for FLYING HY, the Top Hydrogen and Battery Electric Aviation Event
- Century Fasteners Corp. Hires Tony Marano as Director of Human Resources
- Accelerating Toward Commercialization as FDA Momentum, AI Neurotherapy & Manufacturing Expansion Drive Multi-Catalyst Growth Story; N A S D A Q: NRXP
- New Wisconsin Report Shows Most Plane Crashes Happen Outside Major Hubs
- Egypt Selects Gonzaga University and City of Spokane as Team Base Camp Training Site for FIFA World Cup 2026™
- Book Florida Keys Accommodations Early with KeysCaribbean and Save 15 Percent
- Color Card Administrator Highlights Growing Enterprise Demand for Workflow Orchestration in Enterprise Business Card Governance
- Tennessee Laws Lead with Psychotropic Drug Testing in Mass Shooting Cases and Comprehensive Reporting: CCHR Urges Nationwide Adoption
- Curious About Mensa? DFW Event Offers a 1-Day Immersion
- Tacoma: Applicants Sought for the Transportation Commission
- Tacoma: Update Homicide Investigation – Arrest – 1200 block of South M Street